Global Strategic Investment Solutions LLC Purchases Shares of 57,875 Orthofix Medical Inc. $OFIX

Global Strategic Investment Solutions LLC acquired a new stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 57,875 shares of the medical device company’s stock, valued at approximately $664,000. Global Strategic Investment Solutions LLC owned 0.14% of Orthofix Medical as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Rubric Capital Management LP boosted its position in shares of Orthofix Medical by 0.7% during the 2nd quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company’s stock valued at $41,497,000 after acquiring an additional 26,769 shares during the last quarter. Juniper Investment Company LLC lifted its position in Orthofix Medical by 23.3% during the fourth quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company’s stock valued at $53,217,000 after purchasing an additional 663,278 shares during the last quarter. Paradigm Capital Management Inc. NY grew its stake in Orthofix Medical by 34.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after buying an additional 858,900 shares in the last quarter. Armistice Capital LLC grew its stake in Orthofix Medical by 18.4% in the 4th quarter. Armistice Capital LLC now owns 2,648,000 shares of the medical device company’s stock worth $40,144,000 after buying an additional 412,000 shares in the last quarter. Finally, Millennium Management LLC grew its position in Orthofix Medical by 86.6% in the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after acquiring an additional 684,850 shares in the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Insider Transactions at Orthofix Medical

In related news, insider Jorge Andres Cedron sold 3,743 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $12.82, for a total value of $47,985.26. Following the completion of the transaction, the insider directly owned 59,006 shares in the company, valued at $756,456.92. This trade represents a 5.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John B. Henneman III acquired 5,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was acquired at an average price of $12.26 per share, for a total transaction of $61,300.00. Following the acquisition, the director owned 90,809 shares of the company’s stock, valued at approximately $1,113,318.34. This trade represents a 5.83% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 189,896 shares of company stock worth $2,293,970. Corporate insiders own 2.70% of the company’s stock.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $11.90 on Tuesday. Orthofix Medical Inc. has a 1 year low of $8.85 and a 1 year high of $16.99. The stock has a market capitalization of $480.96 million, a P/E ratio of -7.87 and a beta of 0.71. The company’s 50-day moving average is $10.49 and its 200 day moving average is $12.32. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.87 and a quick ratio of 1.76.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.16. Orthofix Medical had a negative return on equity of 13.44% and a negative net margin of 7.27%.The business had revenue of $196.71 million for the quarter, compared to analysts’ expectations of $196.40 million. On average, sell-side analysts expect that Orthofix Medical Inc. will post -1.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on OFIX shares. Stifel Nicolaus decreased their price target on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd. Canaccord Genuity Group lowered their price objective on Orthofix Medical from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a report on Tuesday, April 21st. Barrington Research raised their price target on shares of Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday. Finally, TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a report on Thursday, May 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $16.00.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.